PMID- 32769569
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20230918
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Linking)
VI  - 43
IP  - 4
DP  - 2021 May 1
TI  - An Evaluation of a Fluorescence In Situ Hybridization Strategy Using Air-dried 
      Blood and Bone-marrow Smears in the Risk Stratification of Pediatric B-Lineage 
      Acute Lymphoblastic Leukemia in Resource-limited Settings.
PG  - e481-e485
LID - 10.1097/MPH.0000000000001892 [doi]
AB  - Cytogenetic abnormalities (CAs), one of the strongest influencers of therapeutic 
      outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), can 
      be identified by different techniques. Despite several technological advances, 
      many centers with resource-limited settings continue to use either 
      reverse-transcriptase polymerase chain reaction (RT-PCR) and/or fluorescence in 
      situ hybridization (FISH) to identify prognostically relevant CAs. We evaluated a 
      simple and cost-effective triple-probe FISH strategy on air-dried blood and 
      bone-marrow smears and compared its performance with a multiplex RT-PCR-based 
      approach in the prognostication of pediatric BCP-ALL patients. Three hundred 
      twenty BCP-ALL patients were tested prospectively and in parallel by FISH on 
      air-dried blood or bone-marrow smears and RT-PCR. The FISH strategy correctly 
      diagnosed all genetic abnormalities identified by RT-PCR. Prognostically relevant 
      genetic abnormalities were missed by RT-PCR in 24 (8.1%) patients. In another 20 
      children (6%), with samples inadequate for RT-PCR testing (dry taps or due to 
      poor sample quality), a successful FISH testing could be performed on bone-marrow 
      aspirate or trephine-imprint smears. In addition, FISH detected ploidy changes, 
      which could be confirmed by FxCycle Violet-based flow-cytometry. FISH testing on 
      air-dried smears identified more prognostically relevant CAs, provided 
      information on the ploidy status, and could be successfully performed in children 
      with difficulty in bone-marrow sampling.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sharma, Praveen
AU  - Sharma P
AD  - Department of Haematology.
FAU - Rana, Sonia
AU  - Rana S
AD  - Department of Haematology.
FAU - Sreedharanunni, Sreejesh
AU  - Sreedharanunni S
AD  - Department of Haematology.
FAU - Gautam, Arambam
AU  - Gautam A
AD  - Department of Haematology.
FAU - Sachdeva, Man Updesh Singh
AU  - Sachdeva MUS
AD  - Department of Haematology.
FAU - Naseem, Shano
AU  - Naseem S
AD  - Department of Haematology.
FAU - Varma, Neelam
AU  - Varma N
AD  - Department of Haematology.
FAU - Jain, Richa
AU  - Jain R
AD  - Unit of Paediatric Haemato-oncology, Department of Paediatrics, Advanced 
      Paediatric Centre, Post Graduate Institute of Medical Education and Research, 
      Chandigarh, India.
FAU - Bansal, Deepak
AU  - Bansal D
AD  - Unit of Paediatric Haemato-oncology, Department of Paediatrics, Advanced 
      Paediatric Centre, Post Graduate Institute of Medical Education and Research, 
      Chandigarh, India.
FAU - Trehan, Amita
AU  - Trehan A
AD  - Unit of Paediatric Haemato-oncology, Department of Paediatrics, Advanced 
      Paediatric Centre, Post Graduate Institute of Medical Education and Research, 
      Chandigarh, India.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
SB  - IM
MH  - Bone Marrow/*pathology
MH  - Child
MH  - Child, Preschool
MH  - Chromosome Aberrations
MH  - Dried Blood Spot Testing/methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Infant
MH  - Male
MH  - Multiplex Polymerase Chain Reaction
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/genetics/pathology
MH  - Prospective Studies
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sensitivity and Specificity
COIS- The authors declare no conflict of interest.
EDAT- 2020/08/10 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/08/10 06:00
PHST- 2020/04/17 00:00 [received]
PHST- 2020/06/09 00:00 [accepted]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/08/10 06:00 [entrez]
AID - 00043426-202105000-00014 [pii]
AID - 10.1097/MPH.0000000000001892 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2021 May 1;43(4):e481-e485. doi: 
      10.1097/MPH.0000000000001892.